BioVexLab Solutions is a cutting-edge biotechnology company specializing in the isolation, characterization, and application of extracellular vesicles (EVs) from human, bacterial, and plant sources. Leveraging advanced analytical platforms, we focus on scaling up manufacturing yields while ensuring rigorous control of purity. Our work supports fundamental research, accelerates biomarker discovery and drug delivery development, and drives translational biomedical innovation. We partner with academic institutions, biotechnology companies, and clinical research programs to deliver high-quality, reliable solutions that advance scientific discovery.
Our Mission
BioVexLab Solutions is dedicated to advancing extracellular vesicle research by providing specialized analytical services that ensure accurate isolation, characterization, and in-depth biological analysis of nanoscale vesicles across diverse biological systems.
Our Expertise
BioVexLab Solutions integrates multiple complementary analytical platforms to ensure comprehensive extracellular vesicle characterization:
This multi-technology approach enables accurate interpretation of EVs populations and reduces analytical bias.
At BioVexLab Solutions, we combine scientific expertise with advanced analytical technologies to provide high-quality extracellular vesicles data suitable for high-impact research and translational applications.
Our services include:
✔ Standardized EVs isolation and characterization workflows
✔ Multi-platform analytical validation
✔ High reproducibility and quality control
✔ Support for academic and industrial research projects
✔ Rapid project turnaround
✔ Dedicated scientific consultation
Our extracellular vesicle analytical services support a broad range of biomedical and biotechnological research areas.
BioVexLab Solutions collaborates with:
We work closely with partners to design optimized analytical strategies adapted to their scientific objectives and experimental challenges.
BioVexLab Solutions provides integrated analytical workflows covering the complete extracellular vesicles research pipeline-from isolation and characterization to molecular profiling and functional studies. Each project is designed according to the sample origin, biological question, and experimental objectives.
BioVexLab Solutions contributes to scientific advancement through collaborative research and analytical support.
Our goal is to generate high-quality EVs data suitable for high-impact scientific publication.
1-A potential multimodal biomarker - cognitive signature associated with the conversion from subjective cognitive decline to mild cognitive impairment.
Haddad M, Ben Khedher MR, Ouechtati C, Fülöp T; Consortium for the early identification of Alzheimer's disease‐Quebec (CIMA‐Q); Ramassamy C. Alzheimers Dement (N Y). 2026 Apr 11;12:e70240. doi: 10.1002/trc2.70240. eCollection 2026 Apr-Jun. PMID: 41970527
2-Exploring the potential of plasma and adipose mesenchymal stem cell-derived extracellular vesicles as novel platforms for neuroinflammation therapy.
Silva RO, Haddad M, Counil H, Zaouter C, Patten SA, Fulop T, Ramassamy C. J Control Release. 2025 Jan 10;377:880-898. doi: 10.1016/j.jconrel.2024.11.060. Epub 2024 Dec 7. PMID: 39617173
3- Brain penetration of peripheral extracellular vesicles from Alzheimer's patients and induction of microglia activation.
Counil H, Silva RO, Rabanel JM, Zaouter C, Haddad M, Ben Khedher MR, Brambilla D, Fülöp T, Patten SA, Ramassamy C. J Extracell Biol. 2025 Jan 17;4(1):e70027. doi: 10.1002/jex2.70027. eCollection 2025 Jan. PMID: 39830834
4-Donepezil-Loaded Nanocarriers for the Treatment of Alzheimer's Disease: Superior Efficacy of Extracellular Vesicles Over Polymeric Nanoparticles.
Oliveira Silva R, Counil H, Rabanel JM, Haddad M, Zaouter C, Ben Khedher MR, Patten SA, Ramassamy C. Int J Nanomedicine. 2024 Feb 1;19:1077-1096. doi: 10.2147/IJN.S449227. eCollection 2024. PMID: 38317848
5-Implication of Circulating Extracellular Vesicles-Bound Amyloid-β42 Oligomers in the Progression of Alzheimer's Disease.
Ben Khedher MR, Haddad M, Fulop T, Laurin D, Ramassamy C. J Alzheimers Dis. 2023;96(2):813-825. doi: 10.3233/JAD-230823. PMID: 37840502
6-Effect of APOE ε4 allele on levels of apolipoproteins E, J, and D, and redox signature in circulating extracellular vesicles from cognitively impaired with no dementia participants converted to Alzheimer's disease.
Ben Khedher MR, Haddad M, Laurin D, Ramassamy C. Alzheimers Dement (Amst). 2021 Sep 14;13(1):e12231. doi: 10.1002/dad2.12231. eCollection 2021. PMID: 34541286
7-Glutathione: An Old and Small Molecule with Great Functions and New Applications in the Brain and in Alzheimer's Disease.
Haddad M, Hervé V, Ben Khedher MR, Rabanel JM, Ramassamy C. Antioxid Redox Signal. 2021 Aug 1;35(4):270-292. doi: 10.1089/ars.2020.8129. Epub 2021 May 25. PMID: 33637005
8-Apolipoprotein E4-driven effects on inflammatory and neurotrophic factors in peripheral extracellular vesicles from cognitively impaired, no dementia participants who converted to Alzheimer's disease.
Ben Khedher MR, Haddad M, Laurin D, Ramassamy C. Alzheimers Dement (N Y). 2021 Jan 28;7(1):e12124. doi: 10.1002/trc2.12124. eCollection 2021. PMID: 33537405
9-Levels of Receptor for Advanced Glycation End Products and Glyoxalase-1 in the Total Circulating Extracellular Vesicles from Mild Cognitive Impairment and Different Stages of Alzheimer's Disease Patients.
Haddad M, Perrotte M, Ben Khedher MR, Madec E, Lepage A, Fülöp T, Ramassamy C. J Alzheimers Dis. 2021;84(1):227-237. doi: 10.3233/JAD-210441. PMID: 34487040
10-Profile of pathogenic proteins in total circulating extracellular vesicles in mild cognitive impairment and during the progression of Alzheimer's disease.
Perrotte M, Haddad M, Le Page A, Frost EH, Fulöp T, Ramassamy C. Neurobiol Aging. 2020 Feb;86:102-111. doi: 10.1016/j.neurobiolaging.2019.10.010. Epub 2019 Nov 15. PMID: 31883770
11-Methylglyoxal and Glyoxal as Potential Peripheral Markers for MCI Diagnosis and Their Effects on the Expression of Neurotrophic, Inflammatory and Neurodegenerative Factors in Neurons and in Neuronal Derived-Extracellular Vesicles.
Haddad M, Perrotte M, Khedher MRB, Demongin C, Lepage A, Fülöp T, Ramassamy C. Int J Mol Sci. 2019 Oct 3;20(19):4906. doi: 10.3390/ijms20194906. PMID: 31623327
12-Circulating and Extracellular Vesicles Levels of N-(1-Carboxymethyl)-L-Lysine (CML) Differentiate Early to Moderate Alzheimer's Disease.
Haddad M, Perrotte M, Landri S, Lepage A, Fülöp T, Ramassamy C. J Alzheimers Dis. 2019;69(3):751-762. doi: 10.3233/JAD-181272. PMID: 31127773
BioVexLab Solutions welcomes collaboration requests, service inquiries, and research partnerships.
Contact our team to discuss your research project and receive a customized analytical proposal.
Email:
info@biovexlab.ca
Forms:
Monday
9:00 am - 5:30 pm
Tuesday
9:00 am - 5:30 pm
Wednesday
9:00 am - 5:30 pm
Thursday
9:00 am - 5:30 pm
Friday
9:00 am - 5:30 pm